Scientists identify microglial 'tipping point' that determines who develops dementia

For decades, researchers have puzzled over a stubborn paradox: some people's brains are riddled with the hallmark plaques of Alzheimer's disease, yet their minds remain sharp. They think clearly, remember well, live into their 80s and beyond without cognitive decline. Others with far less pathology slip into dementia. The difference, it turns out, may hinge on a single cellular decision—one that happens inside the brain's immune cells.

A team led by Bart De Strooper and Mark Fiers at VIB-KU Leuven in Belgium, working with Niels Plath at Muna Therapeutics in Copenhagen, has identified what appears to be the critical moment when the brain's defenses either hold or fail. Using advanced mapping techniques on brain tissue from older adults with and without dementia, as well as from cognitively intact centenarians, they discovered that microglia—the brain's primary immune cells—move through six distinct functional states as disease progresses. The transition between these states, they found, is not automatic. It is conditional. And that conditionality may be the key to understanding why some brains resist cognitive decline while others do not.

Microglia are the brain's housekeepers. They patrol neural tissue constantly, clearing away cellular debris and protecting neurons from damage. When amyloid-beta, the sticky protein that accumulates in Alzheimer's disease, first appears in the brain, microglia respond. This initial inflammatory response, the researchers found, is actually protective. The immune cells mobilize, attempt to clear the plaques, and help the brain resist further deterioration. In cognitively healthy people in their 80s who carry substantial amyloid burden, microglia remain locked in this protective state. They do not advance to the next phase.

But as disease progresses and tau protein begins to accumulate inside neurons, something shifts. Microglia transition into a second functional state—one associated with neurodegeneration and cognitive decline. This transition appears to be the tipping point. Once it occurs, the cascade toward dementia accelerates. The researchers identified this shift as the critical boundary between resilience and disease. It is not the presence of amyloid or tau alone that determines outcome. It is whether the brain's immune cells make this particular state transition.

Centenarians presented an intriguing variation. Their microglia did enter the second state, but they did so independently of tau accumulation. Their immune cells remained active and engaged without triggering the usual downstream neural damage. In other words, they had found a way to activate their immune response without falling into the damaging cascade that typically follows.

These findings suggest a fundamental reorientation of how researchers should approach treatment. For years, the focus has been on clearing amyloid plaques—the visible culprit. But the new evidence indicates that the real target should be the microglial state transition itself. By controlling how and when these immune cells shift their functional programs, particularly through signaling pathways like TREM2, it may be possible to preserve the brain's natural resilience. Rather than trying to erase pathology, future therapies might work to keep microglia in their protective state, preventing the transition that leads to cognitive decline.

Plath, chief scientific officer at Muna Therapeutics, framed the implication plainly: the progression from amyloid to tau is not inevitable. It is a dynamic process, potentially modifiable. By mapping the distinct brain environments where resilience and vulnerability diverge, the researchers have identified not just a problem, but a point of intervention. The next phase of Alzheimer's research may focus less on what accumulates in the brain and more on how the brain's own immune system chooses to respond.